1. Surveillance E, End Results (SEER) Program (https://www.seer.cancer.gov). National Cancer Institute.: Cancer Stat Facts: Common Cancer Sites., 2022.
2. Surveillance E, End Results (SEER) Program (https://www.seer.cancer.gov). National Cancer Institute.: Cancer stat facts: prostate cancer., 2022.
3. (ACS) ACS: Cancer facts & Figures. Atlanta, Georgia, 2022.
4. Broughman JR, Fleming CW, Mian OY, Stephans KL, Tendulkar RD. Management of oligometastatic prostate cancer. Appl Radiat Oncol. 2020;9(3):6.
5. Kinsey EN, Zhang T, Armstrong AJ. Metastatic hormone-sensitive prostate cancer: a review of the current treatment landscape. Cancer J. 2020;26:64–75.